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Abstract 1 
A systematic review to identify risk factors for prostate biopsy-related infection, 2 
preventative strategies and optimal management of infectious complications was 3 
conducted. Significant risk factors for post biopsy infection include urogenital infection, 4 
antibiotic use, international travel, hospital exposure, bacteriuria, previous transrectal 5 
biopsy and resistance of faecal flora to antibiotic prophylaxis (especially 6 
fluoroquinolones). Patients at risk may benefit from an adjusted biopsy 7 
protocol comprising transrectal biopsy under targeted prophylaxis, and/or the use of 8 
rectal disinfection techniques or using a transperineal approach. Management of 9 
biopsy-related infection should be based on individual risk and local resistance profiles 10 
with input from multiple specialties. 11 
Keywords: biopsy, complications, fluoroquinolone resistance, prostate, sepsis, 12 
symptomatic infection 13 
 14 
1. INTRODUCTION 15 
Transrectal ultrasound-guided (TRUS) biopsy of the prostate (TRUBP) is the most 16 
commonly used modality to diagnose prostate cancer, resulting in millions of biopsies 17 
performed internationally each year1. Despite reduced PSA testing and biopsy rates 18 
following the U.S. Preventative Services Task Force recommendation in 20122, 19 
widespread use of PSA testing, an ageing population, and increasing implementation of 20 
active surveillance protocols for low risk disease requires prostate biopsy to be 21 
performed in high numbers worldwide. TRUBP is traditionally considered a safe 22 
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procedure but infectious complications can occur; including urinary tract infection (UTI; 1 
>6%), prostatitis, and sepsis (~1%)3, 4 due to particularly Gram-negative 2 
Enterobacteriaceae such as Escherichia coli resulting in substantial health and 3 
economic burden1, 5, 6. TRUBP is considered a ‘contaminated’ procedure under 4 
European Association of Urology (EAU) guidelines, necessitating antibiotic prophylaxis 5 
as a standard of care for all cases7-10. Fluoroquinolone-based prophylaxis is 6 
recommended by many authorities, including the EAU and the American Urological 7 
Association, due to their broad coverage against rectal flora and favourable prostatic 8 
drug penetration11. Duration of prophylaxis is varied, with no evidence to suggest 9 
prolonged duration translates to reduced complications8, 12, 13.  10 
Despite antibiotic prophylaxis, observational studies have reported increasing rates of 11 
infectious complications over the past two decades and postulate a strong association 12 
with changing antimicrobial resistance, especially fluoroquinolone resistance5, 14-18. 13 
Teillant and colleagues have reported that, in the USA, 13,120 post-TRUBP infections 14 
per year are attributable to fluoroquinolone resistance, which would increase to 64,000 15 
infections per year in the event of 100% fluoroquinolone resistance5. The management 16 
of TRUBP complications causes significant financial burden on health systems, reported 17 
to cost more than that due to methicillin-resistant Staphylococcus aureus and 18 
Clostridium difficile in the UK19, 20. The non-financial, unmeasurable burden of disease 19 
from TRUBP complications, including the physical suffering and psychological burden of 20 
significant illness, hospital admission and anxiety regarding future biopsies, must also 21 
be considered21. Furthermore, a recent Federal Drug Administration warning of 22 
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disabling and potentially permanent serious side effects associated with fluoroquinolone 1 
therapy warrants consideration22. 2 
 3 
While resources available to urologists, such as the American Urological Association 4 
White Paper on the Prevention and Treatment of Common Complications Related to 5 
Prostate Biopsy23, partially outline risk factors and management of post-TRUBP 6 
complications, this review sought to critically appraise and summarise available 7 
published literature on risk factors, prevention and management of TRUBP-associated 8 
infectious complications. The available evidence was reviewed in the context of 9 
spreading multi-drug resistance (MDR) to provide recommendations for general use in 10 
modern international urology practice.  11 
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2. MATERIALS AND METHODS 1 
A systematic literature search was conducted in January 2016 in accordance with the 2 
PRISMA statement and Cochrane Guidelines24. The Cochrane Central Register of 3 
Controlled Trials (CENTRAL), PubMed, EMBASE, and LILACS databases were 4 
searched for the following key terms: prostat*, biopsy, infect*, culture*, bacter*, sepsis, 5 
fever, UTI. Only peer reviewed manuscripts were considered for inclusion. 6 
A total of 4,545 citations were identified, including review of reference lists of included 7 
manuscripts for applicable studies. After exclusion of duplicates and screening by title 8 
and abstract, 737 were considered for full text review with 120 included in the final 9 
qualitative review (Supplementary Figure 1).  10 
Studies were rated according to the level of evidence (LoE) and the grade of 11 
recommendation (GoR) similar to the EAU guidelines (2015) modified from the Oxford 12 
Centre for Evidence-based Medicine25. Overall, included studies contained limited 13 
randomised data for most scenarios, and consequently the LoE was mostly 2A/2B and 14 
GoR B.  15 
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3. RESULTS 1 
3.1 Incidence  2 
Complications following TRUBP are reported with great variability and subject to a lack 3 
of complication-specific standardised definitions and follow up. Furthermore, the 4 
incidence of complications varies per the geographic region in which studies are 5 
conducted. Across published reports, a wide-ranging incidence of emergency 6 
department presentations (0 – 6%), hospitalisation (up to 4%), and severe sepsis of 0 – 7 
1% is observed1, 4, 26, 27. In an attempt to standardise complication estimates across 8 
three key measures, hospitalisation, sepsis and acute urinary retention, Bennett and 9 
colleagues performed a systematic review and meta-analysis utilising directly 10 
standardised prevalence estimates based on cases of new prostate cancer cases 11 
according to GLOBOCAN6. The reported estimates are presented in Supplementary 12 
Table 1. 13 
 14 
Many recent reports highlight an increasing incidence of TRUBP-related complications 15 
with time in parallel with a worldwide trend of increasing antimicrobial resistance and 16 
subsequent infection with fluoroquinolone resistant micro-organisms1, 7, 17, 28-30. Despite 17 
this trend, 30-day mortality estimates remain between 0.1 – 1%15-17, 28, 31-33. As 18 
fluoroquinolones are the predominant antimicrobial used for TRUBP prophylaxis, 19 
estimates of fluoroquinolone resistance have been included in Supplementary Table 1 20 
and graphically represented in Supplementary Figure 2.  21 
 22 
 23 
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3.2 Risk factors 1 
An appreciation for risk factors predictive of post-TRUBP infection allows the treating 2 
urologist to guide prophylaxis, as well as assist in patient selection for alternative 3 
sampling methods34. Reported risk factors for post-TRUBP infection are listed in Table 4 
1. 5 
 6 
3.2.1 Host-related 7 
3.2.1.1 Antimicrobial resistance 8 
With fluoroquinolone therapy being most commonly used for TRUBP prophylaxis, the 9 
risk factor most predictive of post-TRUBP infection is fluoroquinolone resistance in 10 
rectal flora16, 17, 26, 27, 32, 35-39. TRUBP causes translocation of rectal bacteria across the 11 
rectal mucosa into the prostate and bloodstream. The mechanism of antimicrobial 12 
resistance development in rectal flora is presumably either induced by selection 13 
pressure following fluoroquinolone use, or acquired by travel to areas of high endemic 14 
antimicrobial resistance4, 35, 40-43. Fluoroquinolone resistance in E. coli blood stream 15 
isolates has been reported to average 12% in the United States and 20% in Europe, 16 
with known fluctuation between 10 and 45% secondary to regional differences4. The 17 
prevalence of fluoroquinolone resistance has been observed to be higher in Asian 18 
countries (26.7 – 92%)44, 45.  19 
A recent meta-analysis, reporting on nine studies and 2,541 patients, reported that 20 
prevalence of fluoroquinolone resistance in rectal flora may be higher (20.4% vs. 21 
12.8%) after fluoroquinolone therapy prior to TRUBP. There was a higher incidence of 22 
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TRUBP-associated infections in patients with fluoroquinolone resistant rectal cultures 1 
compared with fluoroquinolone sensitive (7.1% vs. 1.1%), which translated to a 7.4% vs. 2 
1.4% risk difference, respectively37. These findings were supported by a collaborative 3 
analysis of the original source data, with fluoroquinolone resistance associated with an 4 
increased overall risk of infection (OR 3.98, 95% CI 2.37-6.71) and hospitalisation (OR 5 
4.77, 95% CI 2.50-9.10), which were highest with fluoroquinolone monotherapy39.  6 
 7 
3.2.1.2 Prior urogenital infection and/or antibiotic use 8 
Many studies in patients undergoing TRUBP have reported antimicrobial use within the 9 
past 3-6 months to be significantly associated with fluoroquinolone resistant carriage in 10 
the rectal flora17, 34, 38, 40, 46, 47. These findings have been corroborated using meta-11 
analysis, with history of genitourinary infection (OR 2.56; 95% CI 1.13 – 5.79; n = 1,218) 12 
and prior fluoroquinolone use (OR 4.12; 95% CI 2.30 – 7.37; n = 1,356) reported to be 13 
significant risk factors for fluoroquinolone-resistance colonisation37. Wagenlehner and 14 
colleagues demonstrated on rectal swab culture that single dose prophylaxis was 15 
sufficient to select for ciprofloxacin resistant organisms, with a four-fold increase in 16 
fluoroquinolone resistance after administration43. This has also been demonstrated in 17 
studies investigating empiric antibiotics for elevated PSA, with extended antibiotic 18 
administration leading to significantly higher rates of sepsis and resistance following 19 
biopsy48. Given the high concordance between fluoroquinolone resistance and 20 
extended-spectrum beta-lactamase (ESBL) production, it is unsurprising that the use of 21 
fluoroquinolone prophylaxis has also been shown to co-select for ESBL-producing E. 22 
coli49.  23 
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 1 
3.2.1.3 Hospital admission or exposure (healthcare worker) 2 
Hospitalisation in the year preceding biopsy has also been shown to increase carriage 3 
of fluoroquinolone resistant organisms and increase biopsy related infection11, 17, 38, 50. 4 
Interestingly, this risk has also been observed in physicians51, as well as relatives of 5 
hospital employees52.  6 
 7 
3.2.1.4 Recent international travel 8 
International travel, particularly involving contact with healthcare facilities, also 9 
increases carriage of resistant organisms34, 40. This was particularly true of exposure to 10 
healthcare facilities and water sources in the Indian subcontinent and South-East Asia, 11 
where resistance rates are known to be high6, 42, 53. 12 
 13 
3.2.1.5 Bacteriuria (pre-biopsy urine culture, indwelling catheter in situ) 14 
Asymptomatic bacteriuria is an established risk factor and routine testing is 15 
recommended in the EAU guidelines, though poor compliance with this 16 
recommendation is reported1, 54. History of urethral catheterisation or prior urogenital 17 
infection (urinary tract infection or prostatitis) are also risk factors33, 46, 55. 18 
 19 
 20 
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3.2.1.6 Co-morbidities  1 
The presence of co-morbidities such as diabetes mellitus, cardiac valve replacement, 2 
chronic obstructive pulmonary disease, immunosuppression, or benign prostatic 3 
hyperplasia have been variably reported to increase the risk of post-TRUBP 4 
complications. Higher comorbidity scores have also been associated with a significantly 5 
increased risk of hospitalisation post-biopsy in multiple large retrospective cohorts14, 33, 6 
56. Diabetes and the metabolic syndrome have been reported to be associated with both 7 
increased risk of infectious complications, and carriage of resistant organisms15, 33, 57-59. 8 
However, on meta-analysis of available risk factors, diabetes (OR 1.37; 95% CI 0.77 – 9 
2.46; n=1,140) was not significantly associated with fluoroquinolone-resistant 10 
colonisation37. 11 
 12 
3.2.1.7 Compliance 13 
Non-compliance is difficult to reliably assess but may contribute to complication rates, 14 
as high as 43%, in populations with a relatively low baseline prevalence of 15 
fluoroquinolone resistance60. Of greater concern, the compliance of the treating 16 
urologist to best practice guidelines can influence sepsis outcomes, with a large 17 
multicenter study by Bruyere and colleagues reporting noncompliance with antibiotic 18 
prophylaxis guidelines to be a risk factor for post-TRUBP sepsis (OR 2.3, 95% CI 1.4 - 19 
3.9)46.  20 
 21 
 22 
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3.2.2 Surgeon related 1 
3.2.2.1 Mode of biopsy 2 
Standard TRUBP has many pitfalls which are well known to urologists, thus alternative 3 
methods are discussed here. Transperineal biopsy is an alternative method of sampling 4 
providing transcutaneous access to the prostate, facilitated by the recent 5 
implementation of MRI-fused prostate biopsy methodology18, 61. As prostate cancer 6 
detection rates have been reported to be similar, transperineal prostate biopsy has 7 
typically been reserved for patients at high risk of sepsis, or for repeat biopsies, 8 
especially those with a previous non-diagnostic TRUBP for better detection of anteriorly 9 
sited tumours3, 18, 62, 63. Transperineal sampling allows thorough skin preparation in line 10 
with typical surgical procedures, and prophylactic antibiotics (eg cephazolin) are 11 
targeted to skin flora and common urinary pathogens64, 65.  As transperineal biopsies 12 
avoid the rectum, this approach has traditionally been thought to have lower rates of 13 
infection than the ‘transfaecal’ route of TRUBP. Transperineal biopsy has been 14 
classified as a ‘clean-contaminated’ procedure in the EAU guidelines, however it could 15 
even be argued that it is ‘clean’ as there is often no breach of urinary tract mucosa 16 
using this approach66. This benefit is less clear in practice, and studies with direct 17 
comparison of morbidity between transrectal and transperineal biopsy are lacking. 18 
Recent reports suggest zero or near-zero sepsis rates with the transperineal 19 
procedure3, 65, further supported by three large cohort studies totaling 8,093 patients 20 
with one case of urosepsis reported and recent meta-analysis estimate of 0.1%6, 67-69. 21 
From an antimicrobial stewardship perspective, transperineal biopsy may also avoid 22 
selecting for fluoroquinolone- or multi-resistant bacteria, and stem the increasing 23 
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reliance on an ever-expanding range of antibiotics for biopsy prophylaxis. These clear 1 
benefits in decreasing infection related morbidity are at the expense of higher logistical 2 
and time considerations, requiring admission to hospital, an operating theatre, and 3 
usually general anaesthesia. Transperineal biopsy is also associated with higher rates 4 
of post-procedure urinary retention6, as shown in Supplementary Table 1.  5 
Multi-parametric magnetic resonance imaging (mp-MRI) has emerged in recent years 6 
as a valuable tool in the diagnosis and monitoring of prostate cancer61. Tissue diagnosis 7 
with MRI-guided biopsies is generally via the transrectal route, and preliminary 8 
experience suggests that complication rates are less than the conventional TRUS 9 
approach18, 61. Improved localisation with mp-MRI can reduce unnecessary biopsies, as 10 
well as the need for repeat biopsy in patients on active surveillance18, 61, 70, 71. The 11 
availability and appropriateness of MRI-guided biopsy remains limited, with 12 
approximately 10% of significant lesions deemed ‘MRI-invisible’, so systematic cores 13 
remain necessary61, 71.   14 
 15 
3.2.2.2 Number of cores 16 
The extent of sampling has also been a target for risk reduction. An ‘extended’ biopsy 17 
strategy of 12-18 cores is currently recommended to optimise cancer detection, and 18 
does not increase complications compared to sextant biopsy72, 73. Biopsies of >18 cores 19 
do however have a poor side-effect profile and so called ‘saturation’ biopsies (>20 cores 20 
including transition zone) are rarely indicated72, 74. 18-gauge needles are the most 21 
widely used for sampling, and produce similar specimen quality to 16- and 14-gauge 22 
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needles with low morbidity75. Local anaesthetic administration has also not been 1 
associated with increased infectious complications46.  2 
 3 
3.2.2.3 Previous biopsies 4 
Repeat biopsies are indicated for active surveillance of low risk disease, or in men with 5 
persistent suspicion of prostate cancer according to elevated PSA, abnormal DRE, or 6 
suspicious appearance on imaging76. Reports regarding the association between repeat 7 
biopsies and an increased risk of infectious complications compared with initial biopsies 8 
are mixed31, 46, 77. Any potential risk is concerning in this context, with a retrospective 9 
analysis reported increased odds of an infection (OR 1.33, 95%CI 1.01 - 1.74) for every 10 
previous biopsy in 591 consecutive men undergoing TRUBP77. Repeat biopsy has been 11 
reported to be a risk factor for colonisation with resistant E. coli strains78, with a 12 
progressive increase reported for each biopsy undertaken79. Post-biopsy complications 13 
have been reported to reduce rates of repeat biopsy in men undergoing active 14 
surveillance80. 15 
 16 
Table 1 presents a risk assessment questionnaire, based on available data, to aide 17 
clinicians in assessing the potential for fluoroquinolone resistance and subsequent risk 18 
of post-TRUBP complication. 19 
 20 
 21 
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3.3 Prevention strategies 1 
3.3.1 Antimicrobial prophylaxis – Empiric versus Culture-directed (Targeted) 2 
An evolving body of evidence supports either an expanded antibiotic protocol or one 3 
targeted to rectal cultures on fluoroquinolone-impregnated MacConkey agar plates81. 4 
Expanded antibiotic protocols can consist of either a broad-spectrum antibiotic or the 5 
use of multiple antibiotics, both being a selective force for emergence of multi-resistant 6 
pathogens. 7 
Targeted prophylaxis aims to lower the risk of post-TRUBP infection due to resistant 8 
pathogens and serves to facilitate antimicrobial stewardship, as supported by Liss and 9 
colleagues39. Meta-analysis of available data in 2014 comprising 2,541 patients 10 
estimated higher infection rates when empirical prophylaxis was used (3.3%, 95% CI 11 
2.6-4.2%) than those using targeted methods (0.3%, 95% CI 0-0.9%)37. In contrast, 12 
multiple studies, including a large retrospective North American multicenter database 13 
from over 5,000 patients, in which up to 34% received targeted prophylaxis, have 14 
observed no difference in complications between targeted and empiric prophylaxis 15 
groups27, 36, 82, 83. It has been suggested that patients undergoing repeat biopsy require 16 
repeat culture prior to each biopsy84 and targeted prophylaxis. While potential financial 17 
benefits toward antimicrobial stewardship and potentially for infectious complications 18 
averted are substantial85, further assessment in a randomized controlled trial is 19 
required.  20 
 21 
 22 
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3.3.2 Decontamination  1 
Adjunct strategies of ‘decontamination’ prior to biopsy including bowel preparation and 2 
disinfection of the rectal mucosa are aimed at reducing the bacterial load involved in the 3 
inherently ‘dirty-to-clean’ passage of the TRUBP biopsy needle. Decontamination 4 
strategies for TRUBP biopsy are inconsistently practiced and reported less compared to 5 
antimicrobial-related studies12, 86.  6 
 7 
3.3.2.1 Rectal disinfection 8 
Povidone-iodine rectal preparation (PIRP) is simple and affordable, not associated with 9 
selection of resistant bacteria, and proven safe for colorectal surgery87. From meta-10 
analysis of seven controlled trials (n = 2,049) of rectal disinfection using PIRP prior to 11 
TRUBP, significant reductions in fever, bacteruria and bacteraemia (RR 0.31; 95% CI 12 
0.21 – 0.45) regardless of prophylaxis used have been reported88. Recent retrospective 13 
studies further report significant reductions in infectious complications when PIRP was 14 
used89, as well as in conjunction with targeted prophylaxis90. However, a randomised 15 
controlled trial of prophylactic povidone-iodine use demonstrated insignificantly reduced 16 
complication rates (2.6%) compared with control (4.5%), in a study that is likely to have 17 
been underpowered91. The optimal method of administering PIRP has not been fully 18 
elucidated but the use of a suppository or gauze soaked in povidone-iodine has been 19 
reported to be superior to a rectal enema88, 92. 20 
 21 
 22 
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3.3.2.2 Rectal cleansing 1 
Preparation with a rectal cleansing enema (eg Fleet sodium phosphate) is used by a 2 
minority (18 – 30%) of urologists13 based on mixed results in currently available 3 
evidence8, 30, 93-96.  4 
Recommendations for assessment and prevention of prostate biopsy related infection 5 
arising from this collaborative systematic review are presented in Table 2.  6 
 7 
3.4 Management of prostate biopsy related infection  8 
When considering the optimal treatment for a patient with an infectious complication 9 
following prostate biopsy, several factors need to be considered.  This includes the 10 
severity of the clinical presentation, the likelihood of resistance to empirical antibiotics, 11 
the co-morbidities of the host and whether anatomical complications co-exist (such as 12 
prostate abscesses or urinary tract obstruction). Choosing appropriate initial therapy is 13 
critical as these infections can progress quickly and may result in life-threatening 14 
complications. Inadequate or delayed empirical therapy has been associated with 15 
excess mortality in Gram-negative sepsis, especially in the setting of a high background 16 
prevalence of ESBL-producers97-99. Furthermore, inadequate empirical therapy is not 17 
uncommon in the setting of post-TRUBP sepsis, occurring in 36% of patients in one 18 
study35.  19 
 20 
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3.4.1 Initial assessment and risk of infection with a multi-drug resistant (MDR) 1 
organism 2 
Obtaining a detailed history of recent antibiotic use may help assess the risk of 3 
resistance and, if fluoroquinolones have been used for prophylaxis, this class of drug 4 
should be avoided for empirical therapy.  As noted previously, a significant risk factor for 5 
the likelihood of infection with a multi-drug resistant pathogen, is recent travel to a 6 
country highly endemic for Gram-negative resistance within the preceding 6 months100. 7 
The prevalence of resistance mechanisms such as ESBLs or carbapenemases in 8 
Gram-negative uropathogens varies widely across the world, and the situation is 9 
dynamic. Carbapenemase-producers tend to also possess numerous other resistance 10 
determinants, rendering them multi-drug resistant (MDR), extensively-drug resistant 11 
(XDR) or even pan-drug resistant (PDR)101, 102.  Clearly this can dramatically reduce 12 
treatment options and makes selecting effective empirical therapy extremely 13 
problematic should these strains become predominant.   In some patients, who are 14 
known to be colonised with MDR pathogens, alternatives to TRUBP or avoidance of any 15 
interventional procedure may have to be considered given the risks involved103. 16 
Risk prediction scores for assessing the likelihood of infections with an ESBL-producing 17 
organism in the context of Gram-negative sepsis have been developed, but require 18 
validation in a local context before they can be reliably implemented104, 105.  A simple 19 
decision-support algorithm to help identify patients with bacteremia caused ESBL-20 
producers has been recently published, which used 5 clinical variables within a 21 
classification tree determined by machine-learning methodology: prior history of 22 
colonization/infection with ESBL, chronic indwelling vascular hardware, age ≥43 years, 23 
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recent hospitalization in an ESBL-high burden region and ≥6 days of antibiotic exposure 1 
in the preceding 6 months106. In a retrospective cohort of 1,288 patients with 2 
bacteremia, this approach demonstrated positive and negative predictive values of 3 
90.8% and 91.9% respectively106. However, this model has only been derived from a 4 
single centre in the US and requires validation in other cohorts.  Pre-biopsy rectal 5 
culture may also facilitate identification of antimicrobial resistance and help guide 6 
treatment of biopsy-related sepsis, with one study demonstrating a high concordance 7 
between rectal and urine or blood cultures in patients with sepsis107. 8 
 9 
3.4.2 Early recognition of infectious complications 10 
It is important for patients undergoing TRUBP to be made aware of the signs and 11 
symptoms of infection should they occur post procedure. The early recognition and 12 
effective treatment of sepsis is a key factor in improving patient outcomes, and 13 
management should broadly follow international guidelines, such as those of the 14 
Surviving Sepsis Campaign108. 15 
 16 
3.4.3 Empirical therapy for infectious complications 17 
Empirical regimens must have adequate coverage to reflect local patterns of resistance 18 
in key uropathogens, especially Gram-negative bacteria such as E. coli. Most 19 
microbiology laboratories can provide antimicrobial susceptibility data for urinary tract 20 
isolates to inform local guidelines, or this information may be available from national 21 
surveillance data109.  22 
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Given the difficulty in reliably predicting susceptibility to empirical treatment regimens, it 1 
is critical that appropriate microbiological specimens are collected for culture, including 2 
a mid-stream urine and blood cultures, if the patient is febrile or shows other signs of 3 
sepsis. An advantage for the routine use of pre-biopsy rectal screening (close to the 4 
date of biopsy) is that positive cultures can guide empirical therapy, given a known 5 
concordance between positive rectal and urine or blood cultures in patients with 6 
sepsis107. 7 
In general, given the association with fluoroquinolone prophylaxis and MDR-E. coli 8 
infections, patients presenting with urinary sepsis post-TRUBP will require a broader 9 
spectrum of antibiotic coverage than patients with community-onset infections without 10 
prior healthcare exposure7. Therapy with agents such as 3rd generation cephalosporins 11 
(e.g. ceftriaxone or ceftazidime), amoxicillin-clavulanate, fluoroquinolones or gentamicin 12 
may have a high likelihood of resistance in this context. Broader-spectrum empirical 13 
options need to be considered.  This could include piperacillin-tazobactam or 14 
carbapenems. Amikacin, usually in combination with a beta-lactam agent, may also be 15 
considered given that it frequently retains better in vitro activity than gentamicin against 16 
E. coli isolated from patients with post-TRUBP sepsis35and has shown an additive 17 
benefit in reducing post-TRUBP infections when used as a prophylactic agent3. 18 
 19 
3.4.4 Directed therapy for MDR Gram negative pathogens 20 
Treatment guidelines for urinary infections often do not adequately address treatment 21 
options for MDR pathogens.  Consultation with an infectious disease practitioner or 22 
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medical microbiologist is recommended for these difficult-to-treat organisms. For 1 
several reasons, carbapenems have been regarded as the treatment of choice for 2 
ESBL-producers110, 111. However, carbapenem resistance has been increasing in many 3 
parts of the world112, prompting reconsideration of drugs that were previously 4 
considered less effective (such as cefepime, beta-lactam/beta-lactamase inhibitor 5 
(BLBLI) drugs, or older agents such as fosfomycin, pivmecillinam, or temocillin). 6 
Although published experience with using fosfomycin for treating infections post TRUBP 7 
are sparse, it has shown broadly similar efficacy in comparison to carbapenems for 8 
patients with lower tract infections caused by ESBL-producers, including for patients 9 
with complicating factors113. It is notable that fosfomycin appears to achieve adequate 10 
prostate tissue levels and may be an option for prophylaxis in patients known to be 11 
colonised with MDR Gram-negative pathogens114, 115. Mecillinam is another 12 
‘rediscovered’ antibiotic that appears effective in vitro against ESBL-producing E. coli116, 13 
however there are no published data with respect to pivmecillinam treatment for men 14 
with infections post-TRUBP. Temocillin, a derivative of ticarcillin, has received renewed 15 
interest in recent years and shows stability to a range of ESBL and AmpC beta-16 
lactamases117.  It has been used in addition to ciprofloxacin for routine prophylaxis prior 17 
to TRUBP in patients at high risk of colonisation with resistant E. coli strains118. Novel 18 
beta-lactam/beta-lactamase inhibitor combinations, such as ceftazidime/avibactam and 19 
ceftolozane/tazobactam may also prove to be useful against MDR or XDR Gram-20 
negatives where few alternatives exist (although neither drug is effective against all 21 
types of beta-lactamases).  Both agents have now received FDA approval for the 22 
treatment of complicated UTI following two phase 3 studies119, 120.  23 
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A management summary for empiric and definitive therapy, once susceptibility results 1 
are known, is included as Table 3.  2 
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4. CONCLUSIONS 1 
Despite heterogeneous reporting, infectious complications following prostate biopsy 2 
appear to be increasing due to fluoroquinolone resistance. Preventing TRUBP-related 3 
infections therefore requires collaboration between colleagues in the fields of urology 4 
and infectious diseases to determine the optimal regimens for prophylaxis and 5 
treatment of sepsis, considering local resistance patterns and patient demographics. 6 
Nonetheless, it is clear with the decreasing effectiveness of prophylaxis and increasing 7 
use of broad spectrum agents that we require a new approach to minimising the harm of 8 
post biopsy complications. Effective preventative strategies are available, including 9 
targeted prophylaxis, extended antibiotic regimes, and the transperineal approach 10 
(Table 2), though the cost effectiveness of these strategies is yet to be elucidated. The 11 
findings here are concordant with those described in the American Urological 12 
Association White Paper on the Prevention and Treatment of Common Complications 13 
Related to Prostate Biopsy23, which also discusses pre-operative education and 14 
institutional-level preventative measures. Randomised evidence is desired to establish 15 
these adjunctive tools to improve patient outcomes. Currently, one randomised trial 16 
assessing targeted versus empiric antimicrobial prophylaxis is underway 17 
(ClinicalTrials.gov identifier NCT01659866), while the efficacy of PIRP is also being 18 
assessed in a randomised setting (NCT02245334; WHO ICTRP CTRI/2016/04/006843). 19 
While randomised comparisons between complications observed from TRUS and 20 
transperineal biopsy approaches are old and sparsely published yet desirable, it is likely 21 
that a large study population derived from multiple centres would be required to obtain 22 
statistical power. In the meantime, our review supports the specific screening for risk 23 
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factors predictive of post biopsy infection, to aid in the selection of patients for these 1 
preventative strategies.  2 
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Supplementary Figure 1. PRISMA flowchart of study selection. From the initial 4545 1 
citations, 120 articles were included in the final qualitative review. 2 
Supplementary Figure 2: Global prevalence of fluoroquinolone resistance in Gram-3 
negative urinary pathogens (adapted from Zowawi et al 112) – data from published 4 
studies or national surveillance databases 2009-2014. 5 
 6 
Table 1: Summary of risk factors and proposed TRUBP Risk assessment 7 
questionnaire. Risk factors should be considered when determining the optimal biopsy 8 
approach and use of adjunctive prevention measures to reduce biopsy-related 9 
complication. A risk assessment questionnaire may help identify patients at an 10 
increased risk of biopsy-related complication. Adapted from Loeb et al3 and Losco et 11 
al51. 12 
Risk factors 
Host related Rectal flora antimicrobial resistance (fluoroquinolone most 
commonly) 
Recent urogenital infection and/or antibiotic use 
Hospital admission or exposure (healthcare worker) 
Recent international travel 
Bacteriuria (pre-biopsy urine culture, indwelling catheter in situ) 
Co-morbidities (Diabetes mellitus, cardiac valve replacement, 
chronic obstructive pulmonary disease, benign prostatic 
hyperplasia) 
Surgeon related Approach – transrectal, transperineal, MRI-guided 
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Repeat biopsy 
Greater number of biopsy cores 
Contaminated ultrasound gel 
Questionnaire 
Rectal flora 
antimicrobial 
resistance  
Recent or recurrent urogenital infection? 
Antibiotic use (especially fluoroquinolone)? 
Recent hospital admission?  
Occupation as healthcare worker? 
Recent international travel (especially South-east Asia or South 
America or South-Europe)? 
Bacteruria Pre-biopsy urine culture indicated? 
Indwelling catheter in situ? 
Co-morbidities  Diabetes mellitus? 
Cardiac valve disease/replacement? 
Chronic obstructive pulmonary disease? 
Benign prostatic hyperplasia? 
Other immunosuppressive disorder or treatment? 
Previous biopsy Previous biopsy? How many? 
 1 
  2 
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Table 2: Recommendations for assessment and prevention of prostate biopsy related 1 
infection arising from this collaborative systematic review. Studies were rated according 2 
to the level of evidence (LoE) and the grade of recommendation (GoR) using a system 3 
used in the EAU guidelines (2015) modified from the Oxford Centre for Evidence-based 4 
Medicine23. 5 
Recommendation LoE GoR 
1. The proportion of patients undergoing TRUS biopsy harbouring 
antibiotic-resistant bacteria in their gut flora is not insignificant. Routine 
quinolone-based prophylaxis may no longer be sufficient for all patients. 
1B A 
2. Risk factors should be identified for all patients scheduled for prostate 
biopsy to determine if an altered prophylaxis regime is to be considered. 
These include:  
2A B 
 Urogenital infection and/or antibiotic use in last 6 months 2A  
 International travel in last 6 months 2A  
 Hospital admission or exposure (healthcare worker) in last 6 
months 
2A  
 Current bacteriuria/indwelling catheter 2A  
 Previous TRUS biopsy 2A  
 Planned saturation biopsy 2B  
3. Patients without risk factors may proceed to TRUS biopsy using 
quinolone-based prophlyaxis following informed consent of their low risk 
of sepsis, as well as clear instruction to seek urgent medical attention if 
they develop symptoms of infection. 
1B A 
4. Patients with risk factors should prompt the clinician to consider:   
 a transperineal biopsy, requiring only single dose prophylaxis 
with IV cephazolin, with risk of sepsis less than 1/1000, OR 
2A/3 B 
 TRUS biopsy following rectal culture and targeted antibiotic 
prophlyaxis according to culture results, AND/OR 
2A B 
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 TRUS biopsy with rectal disinfection using Povidone-iodine 2A B 
 1 
Table 3: Management summary for patients presenting with post-TRUBP sepsis. 2 
Empiric treatment should be region- or hospital-specific and continue until in vitro 3 
susceptibilities become available. Culture-directed treatment is dependent on the 4 
underlying organism and should be implemented when possible. 5 
Indication IV therapy options Oral therapy 
options1 
Remarks 
Empiric management 
Sepsis Refer to local protocol or antibiogram and seek advice from 
infectious disease specialist or microbiologist.  
Consider carbapenems or piperacillin-tazobactam +/- 
aminoglycoside.  
Culture directed management (if susceptible in vitro) 
Enterobacteriace
ae – non-MDR 
strains 
 Gentamicin 
 Ceftriaxone  
 
 
 Amoxicillin +/ 
clavulanate  
 Co-
trimoxazole or 
trimethoprim 
 Fluoroquinolo
ne 
Use narrowest 
spectrum 
according to 
susceptibility 
results. 
Generally 
gentamicin 
should only be 
given for <48h 
ESBL-producing 
Enterobacteriace
ae  
 Carbapenems 
 Piperacillin-tazobactam2 
 Aminoglycoside (may be 
 Fosfomycin  
 Temocillin 
 Pivmecillinam 
If piperacillin-
tazobactam is 
used should 
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susceptible to amikacin, but 
frequently gentamicin 
resistant) 
 Ceftolozane/tazobactam 
 Ceftazidime/avibactam 
 Amoxicillin-
clavulanate2 
  (Co-
trimoxazole or 
Fluoroquinolo
ne but often 
resistant) 
 
be dosed 
maximally (e.g. 
4.5g 6-hourly).  
 
Generally 
aminoglycosid
es should only 
be given for 
<48h and not 
used as 
monotherapy.  
Cefepime 
should be 
dosed at 2g 
Q8h if normal 
renal function 
AmpC-producing 
Enterobacteriace
ae (e.g. 
Enterobacter 
cloacae/aerogene
s, Citrobacter 
freundii, Serratia 
marcescens, 
Morganella 
morganii) 
 Carbapenems 
 Cefepime 
 Piperacillin-tazobactam 
(if susceptible, but 
resistance can develop 
in complex infections) 
 Aminoglycosides 
 Ceftazidime/avibactam 
 
 Co-
trimoxazole or 
trimethoprim 
 Fluoroquinolo
ne 
 Fosfomycin 
 Temocillin 
 
Pseudomonas 
aeruginosa 
 Piperacillin-tazobactam 
 Ceftazidime 
 Cefepime  
 (All +/- aminoglycoside) 
Fluoroquinolone 
(Only oral agent 
active against 
Pseudomonas 
spp.) 
Carbapenem-
resistant / XDR 
organisms 
 Ceftazidime/avibactam: 
(for KPC, some OXA-type 
carbapenemase; not NDM 
or IMP types) 
 Ceftolozane/tazobactam: 
often effective for MDR-
Pseudomonas spp.  
Usually very few 
oral options 
available 
 
Fosfomycin may 
be effective  
Seek specialist 
advice; 
carbapenems 
may still be 
used if dosed 
to maximise 
exposure (e.g. 
extended 
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 Combination therapy: e.g. 
carbapenem + polymixin 
(or aminoglycoside, e.g. 
amikacin); dual 
carbapenems 
 
infusions) with 
reference to 
the MIC, or 
used in 
combination 
1 Consider IV to oral switch once patient is afebrile, with resolved clinical signs of 1 
sepsis, tolerating oral intake, gastrointestinal absorption is not compromised and source 2 
control has been achieved; longer IV duration may be required if positive blood cultures 3 
or other complications (e.g. undrained abscess). Total duration is typically 7-14 days 4 
2 If susceptible in vitro: use against ESBL-producers is controversial, specialist advice is 5 
recommended 6 
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